CSF markers in amyotrophic lateral sclerosis

Journal of Neural Transmission

Volumn 119, Issue 7, 2012, Pages 747-757

  Tarasiuk, Joanna ^a   Kułakowska, Alina ^a   Drozdowski, Wiesław ^a   Kornhuber, Johannes ^b   Lewczuk, Piotr ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Biomarker; Blood brain barrier; Blood CSF barrier; Cerebrospinal fluid; Motor neuron disease

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ALBUMIN; AMYLOID BETA PROTEIN[1-42]; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COPPER ZINC SUPEROXIDE DISMUTASE; CYSTATIN C; GELATINASE A; GELATINASE B; GLUTAMIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 8; IRON; NEUROFILAMENT PROTEIN; NITRATE; PEROXYNITRITE; PIGMENT EPITHELIUM DERIVED FACTOR; PROGRANULIN; PROSTAGLANDIN E2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TAR DNA BINDING PROTEIN; TAU PROTEIN; UNINDEXED DRUG; URIC ACID; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR HORN CELL; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CELL MIGRATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME ACTIVITY; EXCITOTOXICITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIPID PEROXIDATION; MICROGLIA; MOTONEURON; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; UPREGULATION;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; HUMANS; MOTOR NEURONS; NEUROFILAMENT PROTEINS; OXIDATIVE STRESS; TAU PROTEINS;

EID: 84863462965     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0806-y     Document Type: Review

References (136)

1. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW (2007) Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 4:7
2. Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, Shaw CE, Powell JF, Leigh PN (1999) Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 8:157-164
3. Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, Przedborski S (2002) Increased levels of the proinflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 58:1277-1279
4. Aoyama K, Matsubara K, Fujikawa Y, Nagahiro Y, Shimizu K, Umegae N, Hayase N, Shiono H, Kobayashi S (2000) Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol 47:524-527
5. Apostolski S, NikolićJ, Bugarski-ProkopljevićC, MiletićV, PavlovićS, FilipovićS (1991) Serum and CSF immunological findings in ALS. Acta Neurol Scand 83:96-98
6. Ballabh P, Braun A, Nedergaard M (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16:1-13
7. Bertel O, Malessa S, Sluga E, Hornykiewicz O (1991) Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Res 566:54-60
8. Beuche W, Yushchenko M, Mäder M, Maliszewska M, Felgenhauer K, Weber F (2000) Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. NeuroReport 11:3419-3422
9. Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW (1999) Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 58:719-728
10. Boillée S, Vande Velde C, Cleveland DW (2006a) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52:39-59
11. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006b) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312:1389-1392
12. Boll MC, Alcaraz-Zubeldia M, Montes S, Murillo-Bonilla L, Rios C (2003) Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients. Neurochem Res 28:699-703
13. Bossolasco P, Cova L, Calzarossa C, Servida F, Mencacci NE, Onida F, Polli E, Lambertenghi Deliliers G, Silani V (2010) Metalloproteinase alterations in the bone marrow of ALS patients. J Mol Med (Berl) 88:553-564
14. Brettschneider J, Petzold A, Junker A, Tumani H (2006a) Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 12:143-148
15. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H (2006b) The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 21:291-295
16. Brettschneider J, Petzold A, Süssmuth SD, Ludolph AC, Tumani H (2006c) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66:852-856
17. Brettschneider J, Widl K, Ehrenreich H, Riepe M, Tumani H (2006d) Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neurosci Lett 404:347-351
18. Brooks BR, Miller RG, Swash M, Munsat TL, Diseases WFoNRGoMN (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293-299
19. Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27:723-749
20. Calingasan NY, Chen J, Kiaei M, Beal MF (2005) Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. Neurobiol Dis 19: 340-347
21. Candelario-Jalil E, Yang Y, Rosenberg GA (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158:983-994
22. Cleveland DW, Liu J (2000) Oxidation versus aggregation-how doSOD1 mutants cause ALS? Nat Med 6:1320-1321
23. Consilvio C, Vincent AM, Feldman EL (2004) Neuroinflammation, COX-2, and ALS-a dual role? Exp Neurol 187:1-10
24. Daniel R, He Z, Carmichael KP, Halper J, Bateman A (2000) Cellular localization of gene expression for progranulin. J Histochem Cytochem 48:999-1009
25. Del Bo R, Corti S, Santoro D, Ghione I, Fenoglio C, Ghezzi S, Ranieri M, Galimberti D, Mancuso M, Siciliano G, Briani C, Murri L, Scarpini E, Schymick JC, Traynor BJ, Bresolin N, Comi GP (2011) No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. Neurobiol Aging 32:1157-1158
26. Demestre M, Parkin-Smith G, Petzold A, Pullen AH (2005) The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol 159:146-154
27. Devos D, Moreau C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V, Destée A, Tonnel AB, Just N (2004) Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 62:2127-2129
28. Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47:S233-S241
29. Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33:637-668
30. Engelhardt B (2006) Regulation of immune cell entry into the central nervous system. Results Probl Cell Differ 43:259-280
31. Fang L, Teuchert M, Huber-Aβel F, Schattauer D, Hendrich C, Dorst J, Zettlmeissel H, Wlaschek M, Scharffetter-Kochanek K, Kapfer T, Tumani H, Ludolph AC, Brettschneider J (2010) MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J Neurol Sci 294:51-56
32. Frutiger K, Lukas TJ, Gorrie G, Ajroud-Driss S, Siddique T (2008) Gender difference in levels of Cu/Zn superoxide dismutase (SOD1) in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9:184-187
33. Fujita K, Honda M, Hayashi R, Ogawa K, Ando M, Yamauchi M, Nagata Y (1998) Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: a possible use as an indicator of extent of the motor neuron loss. J Neurol Sci 158:53-57
34. Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R (2011) Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 117:528-537
35. Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR (2007a) Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res 1157:126-137
36. Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, Sanberg PR (2007b) Evidence of compromised bloodspinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE 2:e1205
37. Garbuzova-Davis S, Saporta S, Sanberg PR (2008) Implications of blood-brain barrier disruption in ALS. Amyotroph Lateral Scler 9:375-376
38. Garbuzova-Davis S, Rodrigues MC, Hernandez-Ontiveros DG, Louis MK, Willing AE, Borlongan CV, Sanberg PR (2011) Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res 1398:113-125
39. Gasche Y, Soccal PM, Kanemitsu M, Copin JC (2006) Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 11:1289-1301
40. Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM (1997) Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 150:617-630
41. Goldknopf IL, Sheta EA, Bryson J, Folsom B, Wilson C, Duty J, Yen AA, Appel SH (2006) Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun 342:1034-1039
42. Graves MC, Fiala M, Dinglasan LA, Liu NQ, Sayre J, Chiappelli F, van Kooten C, Vinters HV (2004) Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord 5:213-219
43. Hampel H, Kötter HU, Padberg F, Körschenhausen DA, Möller HJ (1999) Oligoclonal bands and blood-cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Alzheimer Dis Assoc Disord 13:9-19
44. Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118(Pt 3):707-719
45. Henkel JS, Engelhardt JI, Siklós L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH (2004) Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55:221-235
46. Henkel JS, Beers DR, Wen S, Bowser R, Appel SH (2009) Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 72:1614-1616
47. Ihara Y, Nobukuni K, Takata H, Hayabara T (2005) Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Znsuperoxide dismutase mutation. Neurol Res 27:105-108
48. Iłzecka J (2004) Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 106:289-293
49. Janssen JC, Godbolt AK, Ioannidis P, Thompson EJ, Rossor MN (2004) The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia. J Neurol 251:184-188
50. Jonsson PA, Graffmo KS, Andersen PM, Brännström T, Lindberg M, Oliveberg M, Marklund SL (2006) Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 129:451-464
51. Kasai T, Tokuda T, Ishigami N, Sasayama H, Foulds P, Mitchell DJ, Mann DM, Allsop D, Nakagawa M (2009) Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 117:55-62
52. Kawamata T, Akiyama H, Yamada T, McGeer PL (1992) Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140:691-707
53. Keller JN, Mattson MP (1998) Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 9:105-116
54. KokićAN, StevićZ, StojanovićS, BlagojevićDP, Jones DR, PavlovićS, NiketićV, Apostolski S, SpasićMB (2005) Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 10:265-270
55. Kuncl RW, Bilak MM, Bilak SR, Corse AM, Royal W, Becerra SP (2002) Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J Neurochem 81:178-184
56. Kuźma M, Jamrozik Z, Barańczyk-Kuźma A (2006) Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis. Clin Chim Acta 364:217-221
57. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425-1431
58. Lambrechts D, Poesen K, Fernández-Santiago R, Al-Chalabi A, Del Bo R, Van Vught PW, Khan S, Marklund SL, Brockington A, van Marion I, Anneser J, Shaw C, Ludolph AC, Leigh NP, Comi GP, Gasser T, Shaw PJ, Morrison KE, Andersen PM, Van den Berg LH, Thijs V, Siddique T, Robberecht W, Carmeliet P (2009) Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet 46:840-846
59. Leigh PN, Abrahams S, Al-Chalabi A, Ampong MA, Goldstein LH, Johnson J, Lyall R, Moxham J, Mustfa N, Rio A, Shaw C, Willey E, Team KsMCaR (2003) The management of motor neurone disease. J Neurol Neurosurg Psychiatry 74(Suppl 4):iv32-iv47
60. Leonardi A, Aβbruzzese G, Arata L, Cocito L, Vische M (1984) Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol 231:75-78
61. Li TM, Alberman E, Swash M (1988) Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 51:778-784
62. McGeer PL, McGeer EG (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26:459-470
63. Migheli A, Cordera S, Bendotti C, Atzori C, Piva R, Schiffer D (1999) S-100beta protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett 261:25-28
64. Mitchell JD, Borasio GD (2007) Amyotrophic lateral sclerosis. Lancet 369:2031-2041
65. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, Connor JR (2009) A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 72:14-19
66. Miyazaki K, Ohta Y, Nagai M, Morimoto N, Kurata T, Takehisa Y, Ikeda Y, Matsuura T, Aβe K (2011) Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res 89:718-728
67. Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destée A, Tonnel AB, Lassalle P, Just N (2005) Elevated IL-6 and TNFalpha levels in patients with ALS: inflammation or hypoxia? Neurology 65:1958-1960
68. Mussap M, Plebani M (2004) Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 41:467-550
69. Nagai A, Ryu JK, Terashima M, Tanigawa Y, Wakabayashi K, McLarnon JG, Kobayashi S, Masuda J, Kim SU (2005) Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res 1066:120-128
70. Neusch C, Bähr M, Schneider-Gold C (2007) Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve 35:712-724
71. Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, Boom A, Pochet R (2009a) Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res 1301:152-162
72. Nicaise C, Soyfoo MS, Authelet M, De Decker R, Bataveljic D, Delporte C, Pochet R (2009b) Aquaporin-4 overexpression in rat ALS model. Anat Rec (Hoboken) 292:207-213
73. Niebroj-Dobosz I, Jamrozik Z, Janik P, Hausmanowa-Petrusewicz I, Kwieciński H (1999) Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol Scand 100:238-243
74. Niebroj-Dobosz I, Janik P, Sokołowska B, Kwiecinski H (2010) Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol 17:226-231
75. Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987:25-31
76. Noto Y, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, Mori M, Uchiyama T, Isose S, Nasu S, Sekiguchi Y, Fujimaki Y, Kasai T, Tokuda T, Nakagawa M, Kuwabara S (2011) Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler 12:140-143
77. Ono S, Imai T, Shimizu N, Nagao K (2000) Increased expression of laminin 1 in the skin of amyotrophic lateral sclerosis. Eur Neurol 43:215-220
78. Otto M, Bahn E, Wiltfang J, Boekhoff I, Beuche W (1998) Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neurosci Lett 240:171-173
79. Pardridge WM (1999) Blood-brain barrier biology and methodology. J Neurovirol 5:556-569
80. Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7:710-723
81. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, Cudkowicz ME, Newhall K, Peskind E, Marcus S, Ho L (2006) Identification of potential CSF biomarkers in ALS. Neurology 66:1218-1222
82. Philips T, De Muynck L, Thu HN, Weynants B, Vanacker P, Dhondt J, Sleegers K, Schelhaas HJ, Verbeek M, Vandenberghe R, Sciot R, Van Broeckhoven C, Lambrechts D, Van Leuven F, Van Den Bosch L, Robberecht W, Van Damme P (2010) Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol 69:1191-1200
83. PirttiläT, Vanhatalo S, Turpeinen U, Riikonen R (2004) Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. Acta Neurol Scand 109:337-341
84. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH, Bowser R (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95:1461-1471
85. Rebenko-Moll NM, Liu L, Cardona A, Ransohoff RM (2006) Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details. Curr Opin Immunol 18:683-689
86. Reiber H, Ungefehr S, Jacobi C (1998) The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 4:111-117
87. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F (1993) The natural history of amyotrophic lateral sclerosis. Neurology 43:1316-1322
88. Rosen DR (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364:362
89. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelsø C (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67:2013-2018
90. Rothstein JD (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65(Suppl 1):S3-S9
91. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344:1688-1700
92. Ruan Q, Johnson GV (2007) Transglutaminase 2 in neurodegenerative disorders. Front Biosci 12:891-904
93. Rutka JT, Apodaca G, Stern R, Rosenblum M (1988) The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg 69:155-170
94. Ryberg H, Söderling AS, Davidsson P, Blennow K, Caidahl K, Persson LI (2004) Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer's disease. Neurochem Int 45:57-62
95. Saleh IA, Zesiewicz T, Xie Y, Sullivan KL, Miller AM, Kuzmin-Nichols N, Sanberg PR, Garbuzova-Davis S (2009) Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J Neuroimmunol 215:96-101
96. Schymick JC, Talbot K, Traynor BJ (2007) Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 16(Spec No. 2):R233-R242
97. Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 154:194-199
98. Sharma HS (2005) Pathophysiology of blood-spinal cord barrier in traumatic injury and repair. Curr Pharm Des 11:1353-1389
99. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, Kobayashi M (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917:97-104
100. Shoesmith CL, Findlater K, Rowe A, Strong MJ (2007) Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 78:629-631
101. Siddique T, Deng HX (1996) Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 5(Spec No):1465-1470
102. Simpson EP, Yen AA, Appel SH (2003) Oxidative Stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol 15:730-736
103. Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH (2004) Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62:1758-1765
104. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A (2000) Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54:1960-1964
105. Sleegers K, Brouwers N, Maurer-Stroh S, van Es MA, Van Damme P, van Vught PW, van der Zee J, Serneels S, De Pooter T, Van den Broeck M, Cruts M, Schymkowitz J, De Jonghe P, Rousseau F, van den Berg LH, Robberecht W, Van Broeckhoven C (2008) Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology 71:253-259
106. Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, Marouan A, Dib M, Meininger V (2002) Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 193:73-78
107. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 19:1668-1672
108. Strong M, Rosenfeld J (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4:136-143
109. Strong MJ, Kesavapany S, Pant HC (2005) The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 64:649-664
110. Süssmuth SD, Tumani H, Ecker D, Ludolph AC (2003) Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum.Neurosci Lett 353:57-60
111. Süssmuth SD, Sperfeld AD, Hinz A, Brettschneider J, Endruhn S, Ludolph AC, Tumani H (2010) CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 74:982-987
112. Swash M, Ingram D (1988) Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry 51:165-168
113. Tan CF, Eguchi H, Tagawa A, Onodera O, Iwasaki T, Tsujino A, Nishizawa M, Kakita A, Takahashi H (2007) TD P-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 113:535-542
114. Tanaka M, Kikuchi H, Ishizu T, Minohara M, Osoegawa M, Motomura K, Tateishi T, Ohyagi Y, Kira J (2006) Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65:816-825
115. Tohgi H, Ae T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999) Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett 260:204-206
116. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O (2000) Amyotrophic lateral sclerosis mimic syndromes: a populationbased study. Arch Neurol 57:109-113
117. Tsuboi Y, Yamada T (1994) Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 57:859-861
118. Tumani H, Shen G, Peter JB, Brück W (1999) Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? Arch Neurol 56:1241-1246
119. Tumani H, Teunissen C, Süssmuth S, Otto M, Ludolph AC, Brettschneider J (2008) Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn 8:479-494
120. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W (2006) The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762:1068-1082
121. van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzat A, Brouwers N, Vandenberghe R, Sleegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De Pooter T, Peeters K, Mattheijssens M, Vercelletto M, Van den Broeck M, Cruts M, De Deyn PP, Rousseau F, Brice A, Van Broeckhoven C (2007) Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat 28:416
122. Vangilder RL, Rosen CL, Barr TL, Huber JD (2011) Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ther 130:239-247
123. von Bernhardi R, Eugenín J (2004) Microglial reactivity to betaamyloid is modulated by astrocytes and proinflammatory factors. Brain Res 1025:186-193
124. Vorbrodt AW, Dobrogowska DH (2003) Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. Brain Res Brain Res Rev 42:221-242
125. Wada M, Uchihara T, Nakamura A, Oyanagi K (1999) Bunina bodies in amyotrophic lateral sclerosis on Guam: a histochemical, immunohistochemical and ultrastructural investigation. Acta Neuropathol 98:150-156
126. Wilms H, Sievers J, Dengler R, Bufler J, Deuschl G, Lucius R (2003) Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol 144:139-142
127. Wilson ME, Boumaza I, Lacomis D, Bowser R (2010) Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE 5:e15133
128. Winhammar JM, Rowe DB, Henderson RD, Kiernan MC (2005) Assessment of disease progression in motor neuron disease. Lancet Neurol 4:229-238
129. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11:251-253
130. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6:12
131. Yoshida Y, Une F, Utatsu Y, Nomoto M, Furukawa Y, Maruyama Y, Machigashira N, Matsuzaki T, Osame M (1999) Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders. Intern Med 38:133-139
132. Zetterström P, Andersen PM, Brännström T, Marklund SL (2011) Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J Neurochem 117:91-99
133. Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, Jin X, Reis J, Narvaez A, McGrath MS (2005) Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 159:215-224
134. Zhao W, Xie W, Le W, Beers DR, He Y, Henkel JS, Simpson EP, Yen AA, Xiao Q, Appel SH (2004) Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J Neuropathol Exp Neurol 63:964-977
135. Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O'Banion MK, Stojanovic K, Sagare A, Boillee S, Cleveland DW, Zlokovic BV (2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11:420-422
136. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, Lepore V, Serlenga L, Logroscino G, Sregistry (2006) Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci 250:45-49